Coherus (CHRS) Q2 2026 earnings review
LOQTORZI Rebounds, But Cash Runway Enters the Danger Zone
Coherus delivered a solid commercial quarter, shaking off Q1's weather-related weakness to post $13.6M in LOQTORZI net revenue (+15% QoQ). The company's post-biosimilar cost discipline continues to show results, with operating expenses down significantly YoY. However, the balance sheet tells a distressed story: operating cash burn hit $62M in Q2, dragging total cash down to $105.3M (which includes $22.7M in restricted TSA funds). The company is now in a race against the clock to deliver positive pipeline data in October before liquidity becomes a critical emergency.
🐂 Bull Case
LOQTORZI recovered from the Q1 oncology market macro headwinds (severe weather) to post a record high in new patient starts. The 15% QoQ revenue bump shows the underlying demand growth remains intact.
The exit from the biosimilar business and subsequent headcount reductions are sticking. R&D fell 18% YoY to $21.4M, and SG&A dropped 19% YoY to $21.0M.
🐻 Bear Case
Management's prior claims of being funded 'through 2027' are contradicted by the math. With a $62M quarterly operating burn and only $105M in cash, the company faces an imminent need for dilutive financing or an ex-U.S. licensing deal.
The entire long-term valuation hinges on tagmokitug (CCR8) and casdozokitug (IL-27) data expected in October. In a CCR8 landscape where major players like Amgen have failed, this is a massive binary risk.
⚖️ Verdict: 🔴
Bearish. While the commercial product is performing well and costs are down, the alarming rate of cash burn overshadows the operational beats. The company has virtually zero margin for error heading into its H2 2026 clinical readouts.
Key Themes
Cash Burn Contradicts 'Funded Through 2027' Narrative
In Q1 2026, management confidently stated the company was funded through 2027 data readouts. The Q2 financials paint a starkly different reality. Operating cash flow for the quarter was a negative $62M, plunging total cash and equivalents to $105.3M (down from $172M at FY25 year-end). Crucially, this balance includes $22.7M in TSA payables. Stripping that out leaves ~$82M in effective operating cash. At the current burn rate, Coherus has roughly 1.5 quarters of runway left, making an immediate ex-U.S. partnership or equity raise critical.
LOQTORZI Demand Accelerating Past Weather Headwinds
The Q1 2026 sequential decline was effectively categorized as a blip driven by broader oncology macro conditions (severe weather). Q2 2026 saw a sharp re-acceleration with LOQTORZI revenue up 15% QoQ to $13.6M and up 37% YoY. The company recorded its highest number of new patient starts to date and noted improved therapy duration, validating the drug's position as the Category 1 preferred NCCN option for NPC.
Disciplined Expense Base Enhances Leverage
The pivot to a pure-play oncology innovator is flowing through the P&L. Total operating expenses dropped from $55.7M in 25Q2 to $46.6M in 26Q2. The exit from the biosimilar business has sustainably lowered the floor for SG&A (-19% YoY), while optimized trial execution reduced R&D (-18% YoY). If revenue continues scaling, the operating leverage will be substantial.
CCR8 Competitive Graveyard Looms Over Tagmokitug
While Coherus champions tagmokitug's unique pharmacology (no off-target binding, linear PK), the CCR8 target class remains incredibly high-risk. Competitors like Amgen recently halted programs after seeing abysmal efficacy (2 responses in 77 patients). Coherus must prove their molecule is the 'right drug' in October's data readouts. Any signs of weak efficacy in the HNSCC or CRC cohorts could severely impact the stock.
Off-Label Competition in Community Settings
Despite LOQTORZI being the only FDA-approved therapy for NPC, curbing off-label PD-1 use (like KEYTRUDA) remains a structural hurdle. Reaching fragmented community oncologists who only see 1-2 NPC patients per year requires immense and sustained commercial effort, slowing the drug's peak market penetration.
Pipeline Execution Pacing Toward Binary October Catalysts
The future of Coherus rests on the H2 2026 data readouts. Enrollment is now complete for casdozokitug (anti-IL-27) in HCC and tagmokitug (anti-CCR8) in HNSCC and CRC. Management specifically pointed to 'emerging evidence of activity' with tagmokitug in head and neck cancer, teasing a potentially positive October public disclosure that could serve as the cornerstone for a badly needed ex-U.S. licensing deal.
Other KPIs
Improving. Loss narrowed from $(44.9) million in the prior year period. The improvement of roughly $11.6 million YoY is directly attributable to the $4.1M increase in gross profit from LOQTORZI volume growth and a combined $9.9M reduction in operating expenses (R&D and SG&A).
Deteriorating. Cash used in operations worsened from $(72.5) million in the first half of 2025. Despite narrowing net losses, working capital dynamics and timing of payables/receivables have accelerated cash burn, putting extreme pressure on the balance sheet.
Guidance
Accelerating. In prior quarters, management set a target to hit a $15M quarterly run rate 'sometime in 2026'. With 26Q2 coming in at $13.6M (up from $11.8M in Q1), the company is on a realistic trajectory to achieve this commercial goal by Q3 or Q4.
Key Questions
Bridging the Cash Runway Gap
Operating cash burn was $62M this quarter with total cash down to $105M (inclusive of TSA payables). How is the company bridging liquidity from today through the maturity of the October clinical data readouts without triggering highly dilutive financing?
Ex-U.S. Partnership Timeline
You have explicitly stated that ex-U.S. partnerships for casdozokitug and tagmokitug are a core pillar for non-dilutive funding. Do you need the October data to be fully mature to sign a deal, or are term sheets already being negotiated based on blinded or early cuts?
Tagmokitug HNSCC Efficacy Benchmark
You noted 'emerging evidence of clinical activity' for tagmokitug in HNSCC. Given the standard of care (cetuximab) has roughly a 13% ORR, what specific efficacy and durability thresholds are you looking to cross in the October data disclosure to definitively prove your 'right drug' thesis?